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Abstract: The objective of this work was to study the in situ and in vivo nasal absorption 
of paeonol. A novel single pass in situ nasal perfusion technique was applied to examine 
the rate and extent of nasal absorption of paeonol by rats. Various experimental conditions, 
such as perfusion rate, pH, osmotic pressure and drug concentration, were investigated. 
The in situ experiments showed that the nasal absorption of paeonol was not dependent on 
drug  concentration,  and  fitted  a  first  order  process.  The  absorption  rate  constant,  Ka, 
increased  with  an  increase  in  perfusion  speed.  Paeonol  was  better  absorbed  in  acidic 
solutions than in neutral or alkaline solutions. The value of Ka was higher in a hypertonic 
environment  than  under  isotonic  or  hypotonic  conditions.  In  vivo  studies  of  paeonol 
absorption were carried out in rats and the pharmacokinetics parameters of intranasal (i.n.) 
and intragastric (i.g.) administration were compared with intravenous (i.v.) administration. 
The bioavailabilities of paeonol were 52.37% and 15.81% for i.n. and i.g, respectively, 
while Tmax values were 3.05 ±  1.46 min and 6.30 ±  0.70 min. MRT (Mean Residence 
Time) were 23.19 ±  6.46 min, 41.49 ±  2.96 min and 23.09 ±  5.88 min for i.n., i.g. and i.v. 
methods, respectively. The results demonstrate that paeonol could be absorbed promptly 
and thoroughly by i.n. administration in rats.  
Keywords:  paeonol;  nasal  absorption;  in  situ;  single  pass  perfusion  technique; 
pharmacokinetics 
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1. Introduction 
Cortex Moutan, a kind of traditional Chinese medicine from Paeonia Suffruticosa Andr., has the 
function of clearing heat, absorbing clots, cooling and activating blood. Paeonol is an effective micro 
molecule phenolic compound isolated from Cortex Moutan. It is a kind of evaporable white needle 
crystal  with  low  solubility.  Recently,  with  the  continuous  development  of  research  in  natural 
medicines, the clinical application of paeonol has been further extended. Now, paeonol serves as a 
remarkable analgesic, anti-inflammatory and anti-atherosclerosis medicine and plays a protective role 
in  cerebral  ischemia  [1].  In  the  clinic,  paeonol  is  usually  administered  to  patients  orally  or 
intramuscularly. Paeonol can be quickly absorbed by oral administration, but the bioavailability is 
relatively low compared with injection. Nevertheless, the high concentration of Tween-80 and ethanol 
used in injections can exert intense stimulations on muscles and blood vessels.  
In the last decade, intranasal (i.n.) administration has drawn considerable interest since it provides a 
non-invasive method for bypassing first-pass effect and possibly the blood brain barrier [2–4]. The i.n. 
administration could be a hopeful substitution for injection, as drugs can be absorbed sufficiently and 
rapidly into the blood for systemic administration [5] and transported from the nasal cavity to the 
central nervous system [6]. About 40 substances have been reported to reach the brain via the direct 
nose-to-brain pathway [7]. Moreover, the i.n. route is safer than intravenous (i.v.) due to the barricade 
effect of the nasal mucosa. Based on these facts, great importance has been attached to the research on 
the nasal absorption of paeonol. 
In this report, a novel single pass in situ nasal perfusion technique was applied to examine the rate 
and extent of nasal absorption of paeonol by rat. In vivo studies of paeonol were carried out in rats and 
the pharmacokinetics parameters of i.n. and i.g. were compared with that of i.v. administration. 
2. Results and Discussion  
2.1. In Situ Nasal Perfusion Experiments 
Circulatory perfusion technology has been successfully applied to research the nasal absorption of 
drugs in situ over the past several years [8,9]. However, in our preliminary experiments, paeonol was 
found  to  be  absorbed  by  the  circulatory  tubes  made  of  common  materials,  such  as  PVA,  rubber, 
silicone and low absorption silicone (Sani-Tech LA-60). The nasal absorption of paeonol cannot be 
researched by traditional circulation equipment. Therefore, a single pass perfusion device without soft 
tubes of peristaltic pump was innovated to study the nasal absorption of paeonol. This novel equipment 
and  methods  are  also  suited  for  the  research  of  nasal  absorption  of  drugs  that  are  evaporable  or 
absorbable by the tubes. Furthermore, it was found that water in the perfusate could be absorbed 
transnasally by rats. Hence, Ka was calculated through gravimetry adjustment to get more precise and 
reliable results. 
Impact of perfusion speed on nasal absorption of paeonol: Paeonol nasal solutions (100 μg/mL of 
paeonol)  were  prepared  for  in  situ  nasal  perfusion  (see  Experimental  section)  at  the  speed  of 
0.2 mL/min, 0.3 mL/min and 0.4 mL/min, respectively. The results in Table 1 show that the absorption 
of paeonol could be affected by the perfusion speed. 
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Table 1. Ka of paeonol nasal absorption with different perfusion speeds (n = 5, mean ±  S.D.) 
Perfusion Speed (mL/min)  Ka· 10
-2 min
-1 
0.2  88.59 ±  6.47 
0.3  138.57 ±  9.97
** 
0.4  142.66 ±  11.95
** 
**P < 0.01 vs. 0.2. 
Impact of osmotic pressure on nasal absorption of paeonol: Paeonol nasal solutions in purified 
water, normal saline (NS), or 1.8% NaCl solution (100 μg/mL of paeonol) were prepared for in situ 
nasal perfusion. It was shown that paeonol was absorbed better  under conditions of high osmotic 
pressure than in neutral or low osmotic pressure conditions (as shown in Table 2). 
Table 2. Ka of paeonol nasal absorption with different osmotic pressures (n = 5, mean ±  S.D.). 
Solution   Ka· 10
-2min
-1 
Pure Water  91.62 ±  9.26 
NS   88.59 ±  6.47 
1.8% NaCl  109.47 ±  9.54
** 
**P < 0.01 vs. 0.9%NaCl. 
Impact of pH value on nasal absorption of paeonol: Paeonol solutions of pH 4, pH 6.45 and pH 10 
(100  μg/mL  of  paeonol;  the  pH  was  adjusted  by  buffer  solution)  were  prepared  according to  the 
method of preparation of nasal solutions for in situ nasal perfusion. It was shown that paeonol was 
absorbed better in acidic conditions than in neutral or alkaline conditions (as shown in Table 3). 
Table 3. Ka of paeonol nasal absorption with different pH (n = 5, mean ±  S.D.). 
pH Value  Ka· 10
-2min
-1 
4.01  98.97 ±  11.68
** 
6.45  88.59 ±  6.47 
10.0  81.87 ±  17.91 
**P < 0.01vs. pH 6.45 
Impact  of  concentration  on  nasal  absorption  of  paeonol:  Paeonol  solutions  of  50,  100  and 
200 μg/mL were prepared with NS (pH 6.45) according to the method of preparation of nasal solutions 
for in situ nasal perfusion in Section 3. Table 4 shows that absorption of paeonol had no concentration 
dependence . The absorption pattern appeared to follow the first order process, indicating that paeonol 
was transported across the nasal mucosa by passive diffusion. 
Table  4.  Ka  of  paeonol  nasal  absorption  with  different  drug  concentrations  (n  =  5,  
mean ±  S.D.). 
Drug Concentration (μg/mL)  Ka· 10
-2min
-1 
50  88.91 ±  3.66 
100  88.59 ±  6.47 
200  93.76 ±  4.88 Int. J. Mol. Sci. 2010, 11                       
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2.2. In Vivo Studies 
The concentration-time curves resulting from administration of a single dose of paeonol by i.v., i.n. 
and i.g. in rats is shown in Figure 1. The i.v. as well as i.n. curve best fitted a two compartment open 
model.  After  i.v  administration,  the  paeonol  in  plasma  was  eliminated  rapidly.  The  plasma 
concentrations of paeonol decreased from 9.0 μg/mL to 0.9 μg/mL within 30 minutes. In the case of 
i.n. administration, the drug was absorbed rapidly. The Cmax of paeonol reached about 4.0 μg/mL and 
decreased rapidly from 4.0 μg/mL to 0.5 μg/mL within 30 minutes. In the case of i.g. administration, 
the Cmax of paeonol had reached approximately 0.4 μg/mL at the point of 6 min, and then decreased 
rapidly from 0.4 μg/mL to 0.05 μg/mL within 30 minutes. The main pharmacokinetic parameters of the 
plasma after i.v., i.n. and i.g. administration are shown in Table 5. The Kel values were 0.082 min
-1, 
0.14  min
-1  and  0.054  min
-1  for  i.v.,  i.n.  and  p.o.,  respectively.  MRT  for  injection,  nasal  and  oral 
solutions were 23.09, 23.19 and 41.49 min, respectively while AUC (Area Under the Concentration-
Time Curve) values were 111.62, 58.45 and 17.65 μg/mL·min. Our present results demonstrated that 
after the i.n. administration, paeonol could be absorbed rapidly and the bioavailability of paeonol was 
relatively high. 
Figure 1. Concentration of paeonol in plasma (n = 6, mean ±  S.D.) following a single i.v. 
(◆), i.n. (■), or i.g. (▲) administration; calculated dosage of 4 mg·kg
-1 of paeonol in rats. 
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Table  5.  Main  pharmacokinetic  parameters  of  plasma  after  i.v.  and  i.n.  and  i.g. 
administration of paeonol in rats (n = 5, mean ±  S.D.). 
Parameter  Unit  i.v.  i.n.  i.g. 
ka  Min
-1  ﹣  0.73 ±  0.19  0. 43 ±  0.34 
A  µ g· mL
-1  5.51 ±  1.84  6.57 ±  1.68  6.83 ±  3.86 
α    0.14 ±  0.12  0.29 ±  0.14  0. 15 ±  0.03 
B  µ g· mL
-1  4.04 ±  1.75  1.17 ±  0.48  2.25 ±  0.66 
β    0.09 ±  0.11  0.037 ±  0.014  0.018 ±  0.002 
AUC  µ g/mL· min  111.62 ±  14.45  58.45 ±  12.88
**  17.65 ±  3.44
** 
MRT  min  23.09 ±  5.88  23.19 ±  6.46  41.49 ±  2.96
** 
Cmax  µg· mL
-1  8.96 ±  0.84  4.50 ±  1.53
**  0.49 ±  0.10
** 
Tmax  min  ﹣  3.05 ±  1.46  6.29 ±  0.70 
Kel  min
-1  0.08 ± 0.015  0.14 ± 0.044
**  0.053 ± 0.017 Int. J. Mol. Sci. 2010, 11                       
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Table 5. Cont. 
Parameters  Unit  i.v.  i.n.  i.g. 
K12  min
-1  0.065 ± 0.042  0.11 ± 0.078
**  0.057 ± 0.025 
K21  min
-1  0.087 ± 0.058  0.077 ± 0.035  0.05 ± 0.02
** 
T1/2 Ka  min  ﹣  0.87 ±  0.57  2.44 ±  1.33 
T1/2α  min  8.99 ±  6.99  3.16 ±  2.06
**  4.97 ± 1.12
** 
T1/2β  min  21.28 ±  20.41  23.769 ±  16.86
*  39.026 ± 5.10
** 
*P < 0.05 vs. i.v.,
 **P < 0.01 vs. i.v. 
3. Experimental  
3.1. Chemicals, Reagents and Animals 
Paeonol was obtained from the National Institute for the Control of Pharmaceutical and Biological 
Products  (NICPBP,  Beijing,  P.R.  China).  Acetonitrile,  methanol  and  water  were  of  HPLC  grade 
(Qualigens, China) and all other reagents were of analytical grade. Male Sprague Dawley (SD) rats 
(230–250 g) were obtained from WeiTong biotechnology Inc. (Beijing, China), and were kept in a 
controlled-environment breeding room (temperature: 22 ±  1 ° C, humidity: 60 ±  5%, 12-h dark/light), 
with  free  access  to  common  food  and  water  in  the  first  week.  All  experimental  procedures  were 
conducted in accordance with the European Union guidelines for the use of experimental animals and 
approved by the Beijing University of Chinese Medicine Committee on Animal Care and Use. 
3.2. Instrumentation 
The LC used was an SHIMADZU 10AD series LC (SHIMADZU LC- HP Inc. Japan,) with a binary 
pump, on-line degasser, and a thermostated autosampler. The separation was performed on a Prevail 
C18 column (250 × 4.6 mm, 5 μm, Dikma Technology Company, China). 
3.3. Chromatographic Conditions 
The mobile phases were methanol and water (60:40, v/v), and the signal was monitored at 274 nm. 
The flow rate was maintained at 1.0 mL/min. All the samples were centrifuged at 12,000 rpm for 
10 minutes  before  determination.  There  was  a  good  linearity  between  A  and  C  
(A = 5354C + 1783.8 r = 0.9999). The validation parameters of precision (CV less than 1%) were 
acceptable and the lower limit of quantitation was 5.056 μg/mL.  
3.4. Sample Preparation 
3.4.1. In Situ Nasal Perfusion Experiments 
3.4.1.1. Preparation of Nasal Solutions 
0.4% (v/v) of Tween-80 was dissolved in physiological saline and used as the solvent for drugs. 
Paeonol was dissolved according to the ratio of desired concentration for in situ nasal single pass 
perfusion experiments.  Int. J. Mol. Sci. 2010, 11                       
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3.4.1.2. Methods of in Situ Nasal Single Pass Perfusion 
The absorption studies were carried out using the novel in situ nasal single pass perfusion technique 
(as shown in Figure 2). Rats were anesthetized by intraperitoneal injections of urethane (1.2 g/kg body 
weight). An incision was made in the rat neck. The trachea was cannulated with a polyethylene tube to 
allow breathing while another tube was inserted through the esophagus into the posterior part of the 
nasal cavity. The nasopalatine duct was closed with cyanoacrylate glue to prevent the drainage of 
solution from the nasal cavity to the mouth. The tube inserted into the esophagus was connected to a 
storage bottle containing 20 mL drug solution. The whole passage was sealed in order to avoid the 
volatilization of paeonol.  
Figure 2. Diagram of in situ nasal single pass perfusion. 
drug solution
pump
trachea
esophago
Infused Solution
 
The  drug  solution  was  infused  into  the  nasal  cavity  by  the  pressure  generated  from  a peristaltic 
pump  at  a  certain  speed.  After  running  through  the  nasal  cavity,  the  perfusate  was  collected  into  a 
receiving  bottle every 10  minutes  (10,  20,  30,  40,  50  and  60  min  as  scheduled).  The  bottle  with 
perfusate was weighed immediately when it was substituted.  Then, a certain amount of perfusate was 
sampled,  filtrated  and  analyzed  by  HPLC  to  determine  the  content  of  paeonol.  The  first -order  rate 
constant of the absorption of paeonol, Ka, was estimated by Equation (1). 
 
(1) 
where Vin corresponds to volume of drug solution perfused in 10 min; Vout is the volume of outflow 
perfusate received in 10 min (Vout ≈ Wout for density of perfusate approximately equal to 1 g/mL, Wout 
is the weight of outflow perfusate received in 10 min); ν is the speed of perfusion; ρin and ρout are 
concentrations  of  paeonol (mg· mL
-1)  of buffers  in  the entrance  and  exit,  respectively;  Vnose is  the 
volume of the rat nasal cavity (calculated by the volume of drug solution contained in it). The in situ Int. J. Mol. Sci. 2010, 11                       
 
 
4888 
Ka of the nasal absorption groups were compared by one-way ANOVA at the 0.05 significance level, 
and the tests for statistical differences were paired t-tests. (Statistics Analysis System 8.0). 
3.4.2. In Vivo Experiments 
Fifteen Male SD rats, weighing 230~250 g, were randomly assigned to three groups. All animals 
were fasted for 12 hours prior to the experiments and anesthetized with an intraperitoneal injection of 
urethane (1.2 g/kg body weight). About 0.5 mL of injection sample (at a single dose of 4 mg/kg (for 
paeonol)) was either injected via tail vein or administered via nostril by a modified micro-injector as a 
50 μL i.n. solution. For oral administration, 1 mL of solution was intragastriced at a single dose of 
40 mg/kg (for paeonol), the paeonol was dissolved by the complex solvent (88% physiological saline, 
10% ethanol and 2% Tween-80). 0.25 mL of blood was collected from the left carotid artery at 0.5, 1, 
3,  5,  10,  20,  30,  60,  90,  120  min  after  the  drug  administration.  Blood  samples  were  placed  into 
heparinized tubes. After centrifugation, the plasma obtained was stored at -20 ° C until determination. 
An aliquot of 100 μL of plasma sample was placed into a centrifuge tube and 300 μL acetonitrile was 
added.  After  1  min  in  a  vortex,  the  mixture  was  centrifuged  at  12,000  rpm  for  10  min.  20 μL 
acetonitrile solution was injected into the HPLC system. The HPLC conditions were listed above. It 
could be seen that there was a good linearity between C and A (C = 0.00004A - 0.1215, r = 0.9999). 
The validation parameters of precision (CV less than 5%) and accuracy (recovery of ±  20%) were 
acceptable and the lower limit of quantitation was 0.051 μg/mL. The pharmacokinetic parameters 
associated to each animal were estimated using Kinetica 4.4 software. The in vivo pharmacokinetic 
parameters  of  the  i.n.  and  i.v.  and  i.g.  groups  were  compared  by  one-way  ANOVA  at  the  
0.05 significance level, and the statistical difference was analyzed by paired t-tests (Statistics Analysis 
System 8.0). 
4. Conclusions 
Both in modern and traditional pharmaceutics, nasal drug delivery (NDD) is considered to be an 
effective and promising method for drug administration. This route is beneficial for drugs which can 
be absorbed sufficiently and rapidly into the systemic circulation and can be transported adequately to 
the brain as mentioned above. Paeonol is often administered either by injection or orally. However, the 
bioavailability of paeonol is low through oral administration, and the administration by the i.v. route is 
inconvenient. Therefore, our research on the nasal absorption of paeonol is of great values. 
Circulatory  perfusion  technology  has  been  successfully  applied  to  research  the  in  situ  nasal 
absorption of drugs. However, paeonol was found to be absorbed by the circulatory tubes. We took a 
novel single pass perfusion device to study the nasal absorption of paeonol. From investigations of the 
effects of perfusion speed, osmotic pressure, pH value and drug concentration on the in situ nasal 
absorption of paeonol, it was shown that the Ka value would increase with increasing perfusion speed. 
However, a high perfusion speed may cause injury of the nasal mucosa so that the drug absorption is 
accelerated and the measured value may differ from the reality. Therefore, the perfusion speed of 
0.2 mL/min was adopted in subsequent experiments. Under hypertonic conditions, the Ka was greater 
than that in isotonic and hypotonic environments (P < 0.01). This is possibly due to the cells on the 
nasal mucosa shrinking in hypertonic solutions, leading to the opening up of intercellular space. The Int. J. Mol. Sci. 2010, 11                       
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pH  value  of  the  administering  solution  also  influenced  the  nasal  absorption  of  paeonol.  Research 
indicated  that  paeonol  was  better  absorbed  under  acidic  conditions  than  in  neutral  or  alkaline 
conditions, possibly because more paeonol dissociated in neutral or alkaline conditions than in acidic 
conditions. Since drug concentration had no effect on Ka, the absorption of paeonol could be deemed 
as fitting for the first order process.  
Pharmacokinetic studies of paeonol through i.n. administration routes in rats revealed that paeonol 
was rapidly absorbed and quickly eliminated. The Cmax of paeonol by i.n. administration was achieved 
in three minutes. Moreover, after 30 min, the blood concentration of paeonol was lowered to 10% of 
the Cmax. In addition, the relative bioavailability of paeonol by i.n. administration was 52.37%—about 
three-times more than the bioavailability of i.g. administration, which was 15.81%.  
The results of our study, both in situ and in vivo, indicated that paeonol can be absorbed by the 
nasal route. Owing to the safety, convenience and cheapness of nasal administration compared with 
injection treatment, developing new quick-action preparations of paeonol based on NDD technologies 
is valuable, encouraging and worthy of further studies.  
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